Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors.

PubWeight™: 0.79^‹?›

🔗 View Article (PMC 4490060)

Published in Gene Ther on March 19, 2015

Authors

Y Sun¹, S Peng², J Qiu³, J Miao⁴, B Yang², J Jeang², C-F Hung⁵, T-C Wu⁶

Author Affiliations

1: 1] Department of Obstetrics and Gynecology, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China [2] Departments of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
2: Departments of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
3: 1] Departments of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA [2] Department of Obstetrics and Gynecology, Shanghai Tenth People's Hospital of Tongji University Shanghai, Shanghai, China.
4: 1] Departments of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA [2] Department of General Surgery, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China [3] Department of Hepatobiliary and Pancreatic Surgery, The Second Hospital of Dalian Medical University, Dalian, Liaoning, China.
5: 1] Departments of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA [2] Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
6: 1] Departments of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA [2] Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, USA [3] Department of Obstetrics and Gynecology, Johns Hopkins Medical Institutions, Baltimore, MD, USA [4] Department of Molecular Microbiology and Immunology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.

Associated clinical trials:

Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients | NCT01493154

A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 (HPV-003) | NCT01304524

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3) | NCT00988559

Articles citing this ↘

Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine. Proc Natl Acad Sci U S A (2015) 0.84

Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines (2016) 0.79

Novel delivery approaches for cancer therapeutics. J Control Release (2015) 0.79

The stringent response factors PPX1 and PPK2 play an important role in Mycobacterium tuberculosis metabolism, biofilm formation, and sensitivity to isoniazid in vivo. Antimicrob Agents Chemother (2016) 0.75

Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation. Gene Ther (2017) 0.75

Articles cited by this ↗

Global cancer statistics. CA Cancer J Clin (2011) 185.92

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46

Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46

Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res (1996) 6.03

Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest (2001) 2.61

Mucosal imprinting of vaccine-induced CD8⁺ T cells is crucial to inhibit the growth of mucosal tumors. Sci Transl Med (2013) 2.15

Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med (2009) 1.94

Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther (2004) 1.72

Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol (2010) 1.42

Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine (2009) 1.38

Intravaginal immunization with HPV vectors induces tissue-resident CD8+ T cell responses. J Clin Invest (2012) 1.37

Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Rev Med Virol (2009) 1.27

Therapeutic HPV DNA vaccines. Immunol Res (2010) 1.12

A novel mucosal orthotopic murine model of human papillomavirus-associated genital cancers. Int J Cancer (2011) 0.99

Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc (2010) 0.99

A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). Gynecol Oncol (2015) 0.98

Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents. Hum Gene Ther (2011) 0.96

Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ. Clin Cancer Res (2014) 0.93

Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res (2013) 0.92

Control of HPV-associated tumors by innovative therapeutic HPV DNA vaccine in the absence of CD4+ T cells. Cell Biosci (2014) 0.90

Control of HPV infection and related cancer through vaccination. Recent Results Cancer Res (2014) 0.89